Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sentinel, Oncothyreon In Tumor Program Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Sentinel, Oncothyreon In Tumor Program Pact

To develop and commercialize Chk1 program

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sentinel Oncology Ltd. and Oncothyreon Inc. have entered a collaboration agreement for the development of Sentinel’s Checkpoint Kinase 1 (Chk1) program. Oncothyreon will fund additional research at Sentinel directed for the Chk1 target, and will have an exclusive license to develop and commercialize any resulting compounds. Sentinel is eligible to receive preclinical, clinical and commercial milestone payments of as much as $174 million, and royalties on sales.
 
Sentinel has developed a series of potent, selective, orally active Chk1 kinase inhibitors as chemo- and radio-sensitizers. The Chk1 protein has been shown to selectively sensitize tumor cells to DNA damaging agents, enabling effective lower doses and reduction in associated side effects.
 
Robert L. Kirkman, M.D., president and chief executive officer, Oncothyreon, said, “We are pleased to add to our oncology pipeline through this collaboration with Sentinel. Selective inhibitors of Chk1 have implications across a broad range of cancer types and we believe this program has the potential to make a positive impact on the lives of many cancer patients.”
 
Bob Boyle, chief executive officer of Sentinel, said, “We are delighted that Oncothyreon has recognized the value of our Chk1 program. It is an exciting target, and we look forward to capitalizing on Oncothyreon’s expertise in order to drive the program forward into clinical studies.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics